Browsing: Therapeutics

A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.

A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.

A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.

A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.

A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.

An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.

A post-hoc analysis finds exenatide does not change inflammatory or metabolic biomarkers in alcohol use disorder, despite raised baseline inflammation. PICO summary and commentary.

Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…

Summary: In adults with type 2 diabetes, exenatide and glucagon co-infusion significantly increased myocardial glucose uptake and improved markers of…

An early-phase trial reports large but exploratory weight-loss signals for subcutaneous amycretin in overweight and obesity, with safety as the primary focus. PICO summary and expert commentary.